TEAMLAB
8.8.2019 12:48:06 CEST | Business Wire | Press release
This summer marks the one-year anniversaries for art collective teamLab’s two museums in Tokyo: MORI Building DIGITAL ART MUSEUM: teamLab Borderless (Odaiba, Tokyo; hereafter teamLab Borderless) and teamLab Planets TOKYO (Toyosu, Tokyo; hereafter teamLab Planets). In the one year since their openings, teamLab Borderless and teamLab Planets have seen a combined 3.5 million visitors. teamLab Borderless alone welcomed 2.3 million visitors within one year of opening, exceeding the number of attendees at the Van Gogh Museum in the Netherlands and setting a record number of visitors at a single-artist museum in one year. These visitors came from over 160 countries and regions around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190808005373/en/
teamLab Borderless and teamLab Planets are two museums dedicated solely to art by teamLab. teamLab Borderless is a world of ever-changing artworks without boundaries, a “museum without a map.” One year since its opening in June, 2018, the museum has seen approximately 2.3 million visitors from over 160 countries and regions worldwide. teamLab Planets is “a museum where you move through water.” Guests walk barefoot in the space and physically immerse their entire bodies in massive artworks. One year since its opening in July, 2018, the museum has welcomed over 1.25 million visitors from 106 countries and regions around the world.
When compared to the world’s three most-visited single-artist museums of 2018, both teamLab Borderless and teamLab Planets welcomed more visitors than the Picasso Museum in Barcelona, Spain (948,483 visitors), and the Dalí Theatre-Museum in Figueres, Spain (1,105,169 visitors). The number of museum attendees at teamLab Borderless exceeds even those of the Van Gogh Museum in Amsterdam, Netherlands (2,161,160 visitors), making it the world’s most-visited museum dedicated to a single artist. (*1).
- teamLab Borderless (Odaiba, Tokyo)
Of the 2.3 million visitors to teamLab Borderless, approximately 50% come from overseas (*2), with most coming from the USA, followed by Australia, China, Thailand, Canada, and the UK, making it a museum that attracts not only visitors from neighboring countries, but those from far more distant regions as well. In addition, according to a survey conducted by the museum, it appears that about 50% of the guests from overseas visited Tokyo in order to visit the museum (*3).
- teamLab Planets (Toyosu, Tokyo)
Of the 1.25 million visitors to teamLab Planets, approximately 30% come from overseas (*4), with the majority coming from the USA, followed by Hong Kong, Taiwan, the UK, and Australia.
-----------------------
*1 ”THE ART NEWSPAPER SPECIAL REPORT Art’s Most Popular: Exhibition and museum visitor figures 2018” The Art Newspaper. Number 311, April, 2019.
*2 teamLab Borderless Official Website, Ticket Purchasing Data (data obtained Feb 16 - June 7, 2019)
*3 teamLab Borderless Visitor Survey (conducted Oct 25 - Nov 2, 2018), 1,237 respondents
*4 teamLab Planets Official Website, Ticket Purchasing Data (data obtained March 1 - June 30, 2019)
About teamLab
teamLab (f. 2001) is an art collective, interdisciplinary group of ultratechnologists whose collaborative practice seeks to navigate the confluence of art, science, technology, design and the natural world. teamLab aims to explore a new relationship between humans and nature, and between oneself and the world through art. Click here
for full bio.
teamLab is represented by Pace Gallery
.
Press Kit
teamLab Borderless
https://goo.gl/MpzVss
For tickets and more information, please visit borderless.teamlab.art
, and follow Instagram
.
teamLab Planets
https://goo.gl/tQXMLm
For tickets and more information, please visit planets.teamlab.art
, and follow Instagram
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190808005373/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
